What could be a fruitful conversation has been largely co-opted by pharmaceutical companies as a method for trying to get drugs with unclear benefits approved.
A leading FDA panel has voted to pull the premature birth drug Makena from the market by a 14-1 vote. It is likely that the agency will follow by removing it from shelves in the coming days.
WASHINGTON The maker of the only U.S. drug intended to prevent premature births is making a last-ditch effort this week to keep its medication on the market, even as health regulators insist that it doesn t work.
The FDA could soon pull the only available drug believed to prevent premature birth after a 2019 study found that it was not effective. The company is fighting the move this week.